AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SFM
  4. [8-K] Sprouts Farmers Market, Inc. Reports Material Event

[8-K] Sprouts Farmers Market, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (NTLA) 鈥� Form 4 insider filing

EVP & CFO Edward J. Dulac III executed an automatic, non-volitional sale of 7,462 common shares on 23 Jul 2025 at $14.02 per share. The disposition was a mandatory 鈥渟ell-to-cover鈥� to satisfy federal and state tax-withholding obligations triggered by the vesting of RSUs on 22 Jul 2025.

Post-transaction, Dulac directly owns 106,062 NTLA shares; no indirect holdings or derivative security changes were reported. No options were exercised or granted, and the filing does not disclose any additional share sales or purchases.

The event does not materially alter management鈥檚 economic exposure to the company and should be viewed as administrative rather than discretionary trading activity.

Intellia Therapeutics, Inc. (NTLA) 鈥� Comunicazione interna Form 4

Il EVP e CFO Edward J. Dulac III ha effettuato una vendita automatica e non volontaria di 7.462 azioni ordinarie il 23 luglio 2025 a 14,02 $ per azione. La vendita 猫 stata una cessione obbligatoria 鈥渟ell-to-cover鈥� per adempiere agli obblighi di ritenuta fiscale federale e statale derivanti dal vesting delle RSU avvenuto il 22 luglio 2025.

Dopo la transazione, Dulac detiene direttamente 106.062 azioni NTLA; non sono stati riportati cambiamenti in partecipazioni indirette o strumenti derivati. Non sono state esercitate n茅 assegnate opzioni, e la comunicazione non segnala ulteriori vendite o acquisti di azioni.

L鈥檕perazione non modifica in modo significativo l鈥檈sposizione economica del management verso la societ脿 e va interpretata come un鈥檃ttivit脿 amministrativa piuttosto che una negoziazione discrezionale.

Intellia Therapeutics, Inc. (NTLA) 鈥� Presentaci贸n interna Formulario 4

El EVP y CFO Edward J. Dulac III realiz贸 una venta autom谩tica y no voluntaria de 7,462 acciones ordinarias el 23 de julio de 2025 a $14.02 por acci贸n. La disposici贸n fue una venta obligatoria 鈥渟ell-to-cover鈥� para cumplir con las obligaciones de retenci贸n fiscal federales y estatales derivadas del vesting de RSU ocurrido el 22 de julio de 2025.

Tras la transacci贸n, Dulac posee directamente 106,062 acciones NTLA; no se reportaron cambios en participaciones indirectas ni en valores derivados. No se ejercieron ni otorgaron opciones, y la presentaci贸n no revela ventas o compras adicionales de acciones.

El evento no altera materialmente la exposici贸n econ贸mica de la direcci贸n a la empresa y debe considerarse una actividad administrativa m谩s que una operaci贸n discrecional.

Intellia Therapeutics, Inc. (NTLA) 鈥� 雮措秬鞛� Form 4 鞁犼碃

EVP 瓴� CFO Edward J. Dulac III電� 2025雲� 7鞗� 23鞚�鞐� 7,462欤�鞚� 氤错喌欤茧ゼ 欤茧嫻 $14.02鞐� 鞛愲彊鞙茧 牍勳瀽氚滌爜鞙茧 毵る弰頄堨姷雼堧嫟. 鞚措矆 觳橂秳鞚� 2025雲� 7鞗� 22鞚� RSU 甓岆Μ 頇曥爼鞐� 霐半ジ 鞐半癌 氚� 欤� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暅 頃勳垬 鈥渟ell-to-cover鈥� 毵る弰鞓�鞀惦媹雼�.

瓯半灅 頉� Dulac電� 歆侅爲 106,062欤� NTLA 欤检嫕毳� 氤挫湢頃橂┌, 臧勳爲 氤挫湢雮� 韺岇儩靸來拡 氤�霃欖潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 鞓奠厴 頄夓偓雮� 攵�鞐姅 鞐嗢棃瓿�, 於旉皜鞝侅澑 欤检嫕 毵るГ霃� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

鞚措矆 瓯半灅電� 瓴届榿歆勳潣 須岇偓鞐� 雽�頃� 瓴届牅鞝� 雲胳稖鞐� 鞁れ鞝侅澑 氤�頇旊ゼ 欤检 鞎婌溂氅�, 鞛焿鞝� 瓯半灅氤措嫟電� 甏�毽爜鞚� 臁办箻搿� 氤挫晞鞎� 頃╇媹雼�.

Intellia Therapeutics, Inc. (NTLA) 鈥� D茅claration interne Formulaire 4

Le EVP et CFO Edward J. Dulac III a effectu茅 une vente automatique et non volontaire de 7 462 actions ordinaires le 23 juillet 2025 au prix de 14,02 $ par action. Cette cession 茅tait une op茅ration obligatoire de type 芦 sell-to-cover 禄 visant 脿 satisfaire les obligations de retenue d鈥檌mp么t f茅d茅rales et 茅tatiques d茅clench茅es par la lev茅e des restrictions des RSU le 22 juillet 2025.

Apr猫s la transaction, Dulac d茅tient directement 106 062 actions NTLA ; aucun changement dans les participations indirectes ou les titres d茅riv茅s n鈥檃 茅t茅 signal茅. Aucune option n鈥檃 茅t茅 exerc茅e ou attribu茅e, et la d茅claration ne mentionne aucune vente ou achat d鈥檃ctions suppl茅mentaire.

Cet 茅v茅nement ne modifie pas de mani猫re significative l鈥檈xposition 茅conomique de la direction 脿 l鈥檈ntreprise et doit 锚tre consid茅r茅 comme une op茅ration administrative plut么t que comme une transaction discr茅tionnaire.

Intellia Therapeutics, Inc. (NTLA) 鈥� Insider-Meldung Form 4

EVP & CFO Edward J. Dulac III f眉hrte am 23. Juli 2025 einen automatischen, nicht freiwilligen Verkauf von 7.462 Stammaktien zum Preis von 14,02 $ pro Aktie durch. Die Transaktion war ein verpflichtender 鈥濻ell-to-Cover鈥�-Verkauf zur Erf眉llung der bundes- und landesrechtlichen Steuerabzugsverpflichtungen, die durch das Vesting der RSUs am 22. Juli 2025 ausgel枚st wurden.

Nach der Transaktion besitzt Dulac direkt 106.062 NTLA-Aktien; keine 脛nderungen bei indirekten Beteiligungen oder derivativen Wertpapieren wurden gemeldet. Es wurden keine Optionen ausge眉bt oder gew盲hrt, und die Meldung enth盲lt keine weiteren Aktienverk盲ufe oder -k盲ufe.

Das Ereignis 盲ndert die wirtschaftliche Beteiligung des Managements am Unternehmen nicht wesentlich und sollte als administrative, nicht als diskretion盲re Handelsaktivit盲t betrachtet werden.

Positive
  • Executive retains 106,062 shares, indicating continued alignment with shareholder interests.
  • Transaction was pre-programmed and tax-driven, reducing concerns about opportunistic insider selling.
Negative
  • Even administrative insider sales can create superficial bearish headlines that may pressure short-term sentiment.

Insights

TL;DR: Routine sell-to-cover, neutral signal.

The CFO鈥檚 7,462-share sale鈥攐nly ~7% of his 106k-share stake鈥攚as required to cover taxes on vested RSUs, a common practice that avoids out-of-pocket tax payments. Because the shares were disposed automatically and promptly disclosed, the transaction offers little insight into management鈥檚 outlook on NTLA fundamentals. Insider ownership remains significant, supporting alignment with shareholders. I regard the filing as operationally neutral with no valuation impact.

TL;DR: Compliant disclosure, immaterial governance impact.

The form demonstrates timely Section 16 compliance, detailing a tax-driven sale under Rule 10b5-1-like mechanics. Such sell-to-cover transactions are typically pre-approved and avoid potential trading-window issues. Retention of over 100k shares preserves meaningful 鈥榮kin in the game,鈥� and no red flags emerge regarding unusual trading patterns. Governance impact is minimal; investors should focus on broader performance catalysts rather than this single administrative filing.

Intellia Therapeutics, Inc. (NTLA) 鈥� Comunicazione interna Form 4

Il EVP e CFO Edward J. Dulac III ha effettuato una vendita automatica e non volontaria di 7.462 azioni ordinarie il 23 luglio 2025 a 14,02 $ per azione. La vendita 猫 stata una cessione obbligatoria 鈥渟ell-to-cover鈥� per adempiere agli obblighi di ritenuta fiscale federale e statale derivanti dal vesting delle RSU avvenuto il 22 luglio 2025.

Dopo la transazione, Dulac detiene direttamente 106.062 azioni NTLA; non sono stati riportati cambiamenti in partecipazioni indirette o strumenti derivati. Non sono state esercitate n茅 assegnate opzioni, e la comunicazione non segnala ulteriori vendite o acquisti di azioni.

L鈥檕perazione non modifica in modo significativo l鈥檈sposizione economica del management verso la societ脿 e va interpretata come un鈥檃ttivit脿 amministrativa piuttosto che una negoziazione discrezionale.

Intellia Therapeutics, Inc. (NTLA) 鈥� Presentaci贸n interna Formulario 4

El EVP y CFO Edward J. Dulac III realiz贸 una venta autom谩tica y no voluntaria de 7,462 acciones ordinarias el 23 de julio de 2025 a $14.02 por acci贸n. La disposici贸n fue una venta obligatoria 鈥渟ell-to-cover鈥� para cumplir con las obligaciones de retenci贸n fiscal federales y estatales derivadas del vesting de RSU ocurrido el 22 de julio de 2025.

Tras la transacci贸n, Dulac posee directamente 106,062 acciones NTLA; no se reportaron cambios en participaciones indirectas ni en valores derivados. No se ejercieron ni otorgaron opciones, y la presentaci贸n no revela ventas o compras adicionales de acciones.

El evento no altera materialmente la exposici贸n econ贸mica de la direcci贸n a la empresa y debe considerarse una actividad administrativa m谩s que una operaci贸n discrecional.

Intellia Therapeutics, Inc. (NTLA) 鈥� 雮措秬鞛� Form 4 鞁犼碃

EVP 瓴� CFO Edward J. Dulac III電� 2025雲� 7鞗� 23鞚�鞐� 7,462欤�鞚� 氤错喌欤茧ゼ 欤茧嫻 $14.02鞐� 鞛愲彊鞙茧 牍勳瀽氚滌爜鞙茧 毵る弰頄堨姷雼堧嫟. 鞚措矆 觳橂秳鞚� 2025雲� 7鞗� 22鞚� RSU 甓岆Μ 頇曥爼鞐� 霐半ジ 鞐半癌 氚� 欤� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暅 頃勳垬 鈥渟ell-to-cover鈥� 毵る弰鞓�鞀惦媹雼�.

瓯半灅 頉� Dulac電� 歆侅爲 106,062欤� NTLA 欤检嫕毳� 氤挫湢頃橂┌, 臧勳爲 氤挫湢雮� 韺岇儩靸來拡 氤�霃欖潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 鞓奠厴 頄夓偓雮� 攵�鞐姅 鞐嗢棃瓿�, 於旉皜鞝侅澑 欤检嫕 毵るГ霃� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

鞚措矆 瓯半灅電� 瓴届榿歆勳潣 須岇偓鞐� 雽�頃� 瓴届牅鞝� 雲胳稖鞐� 鞁れ鞝侅澑 氤�頇旊ゼ 欤检 鞎婌溂氅�, 鞛焿鞝� 瓯半灅氤措嫟電� 甏�毽爜鞚� 臁办箻搿� 氤挫晞鞎� 頃╇媹雼�.

Intellia Therapeutics, Inc. (NTLA) 鈥� D茅claration interne Formulaire 4

Le EVP et CFO Edward J. Dulac III a effectu茅 une vente automatique et non volontaire de 7 462 actions ordinaires le 23 juillet 2025 au prix de 14,02 $ par action. Cette cession 茅tait une op茅ration obligatoire de type 芦 sell-to-cover 禄 visant 脿 satisfaire les obligations de retenue d鈥檌mp么t f茅d茅rales et 茅tatiques d茅clench茅es par la lev茅e des restrictions des RSU le 22 juillet 2025.

Apr猫s la transaction, Dulac d茅tient directement 106 062 actions NTLA ; aucun changement dans les participations indirectes ou les titres d茅riv茅s n鈥檃 茅t茅 signal茅. Aucune option n鈥檃 茅t茅 exerc茅e ou attribu茅e, et la d茅claration ne mentionne aucune vente ou achat d鈥檃ctions suppl茅mentaire.

Cet 茅v茅nement ne modifie pas de mani猫re significative l鈥檈xposition 茅conomique de la direction 脿 l鈥檈ntreprise et doit 锚tre consid茅r茅 comme une op茅ration administrative plut么t que comme une transaction discr茅tionnaire.

Intellia Therapeutics, Inc. (NTLA) 鈥� Insider-Meldung Form 4

EVP & CFO Edward J. Dulac III f眉hrte am 23. Juli 2025 einen automatischen, nicht freiwilligen Verkauf von 7.462 Stammaktien zum Preis von 14,02 $ pro Aktie durch. Die Transaktion war ein verpflichtender 鈥濻ell-to-Cover鈥�-Verkauf zur Erf眉llung der bundes- und landesrechtlichen Steuerabzugsverpflichtungen, die durch das Vesting der RSUs am 22. Juli 2025 ausgel枚st wurden.

Nach der Transaktion besitzt Dulac direkt 106.062 NTLA-Aktien; keine 脛nderungen bei indirekten Beteiligungen oder derivativen Wertpapieren wurden gemeldet. Es wurden keine Optionen ausge眉bt oder gew盲hrt, und die Meldung enth盲lt keine weiteren Aktienverk盲ufe oder -k盲ufe.

Das Ereignis 盲ndert die wirtschaftliche Beteiligung des Managements am Unternehmen nicht wesentlich und sollte als administrative, nicht als diskretion盲re Handelsaktivit盲t betrachtet werden.

0001575515false00015755152025-07-252025-07-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 25, 2025
Sprouts Farmers Market, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3602932-0331600
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
5455 E. High Street, Suite 111
Phoenix, Arizona 85054
(Address of principal executive offices and zip code)
(480) 814-8016
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 par valueSFMNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 1.01. Entry into a Material Definitive Agreement.
On July 25, 2025, Sprouts Farmers Market, Inc. (“Holdings”) and its subsidiary, Sprouts Farmers Markets Holdings, LLC (“Borrower” and, together with Holdings, the “Company”) entered into a credit agreement (the “Credit Agreement”) with the lenders named therein, JPMorgan Chase Bank, N.A., as administrative agent, an issuing bank and swingline lender, J.P. Morgan Securities LLC, as sustainability structuring agent, Truist Bank and PNC Bank, National Association, as syndication agent, and Bank of America, N.A., BMO Bank, N.A. and US Bank National Association, as documentation agents. The Credit Agreement provides for a senior secured revolving credit facility (the “Revolving Credit Facility”) with an initial aggregate commitment of $600 million, which may be increased from time to time pursuant to the terms set forth in the Credit Agreement. In connection with the closing of the Credit Agreement, the Company terminated its existing $700 million senior secured credit facility. The proceeds of loans under the Revolving Credit Facility will be used for general corporate purposes. The Company had no loans outstanding under the Credit Agreement as of July 25, 2025.

The Credit Agreement is scheduled to mature, and the commitments thereunder will terminate, on July 25, 2030, subject to extensions as set forth in the Credit Agreement.

Loans under the Credit Agreement will initially bear interest, at the Borrower’s option, either at the Term SOFR (with a floor of 0.00%) plus 1.00% per annum or alternate base rate (with a floor of 0.00%) plus 0.00% per annum. The interest rate margins are subject to upward adjustments pursuant to a pricing grid based on the Company’s total net leverage ratio as set forth in the Credit Agreement and to upward or downward adjustments of up to 0.05% based upon the achievement of certain sustainability-linked metric thresholds, as set forth in the Credit Agreement.

The Borrower may prepay loans and permanently reduce commitments under the Credit Agreement at any time in agreed-upon minimum principal amounts, without premium or penalty (except Term SOFR breakage costs, if applicable).

Subject to certain customary exceptions, obligations under the Credit Agreement are guaranteed by the Company and substantially all of the Borrower’s current and future wholly owned material domestic subsidiaries, subject to customary exceptions, and are secured by a first–priority security interest in substantially all of the assets of the Company and its subsidiary guarantors, including, without limitation, a pledge by Holdings of its equity interest in the Borrower, subject to customary exceptions.

The Credit Agreement contains customary representations, affirmative covenants and negative covenants which representations and affirmative and negative covenants are subject to customary and other agreed-upon exceptions. In addition, the Credit Agreement requires that the Borrower and its restricted subsidiaries maintain a maximum total net leverage ratio not to exceed 3.75 to 1.00, as may be adjusted as set forth in the Credit Agreement, and a minimum interest coverage ratio not to be less than 3.00 to 1.00. Each of these covenants is tested on the last day of each fiscal quarter, commencing with the fiscal quarter ending September 28, 2025.

The Credit Agreement also contains customary events of default. If an event of default occurs, the administrative agent and lenders are entitled to take various actions, including the acceleration of amounts due under the Credit Agreement, termination of commitments thereunder and certain other customary actions permitted to be taken upon an event of default by a secured creditor.

A copy of the Credit Agreement is filed as Exhibit 10.1 to this report and is incorporated herein by reference. The foregoing description of the Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Credit Agreement.


Item 1.02. Termination of a Material Definitive Agreement.
The information set forth in Item 1.01 of this Form 8-K is hereby incorporated into this Item 1.02.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 of this Form 8-K is hereby incorporated into this Item 2.03.



Item 7.01. Regulation FD Disclosure.

The registrant is furnishing this Item 7.01 in connection with the disclosure of information, in the form of the textual information from a press release dated July 25, 2025. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later company filing or other means. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information furnished in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

The registrant does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement in the attached press release is based.

The text of this Current Report on Form 8-K and the attached press release are available on the registrant’s investor relations website located at investors.sprouts.com, although the registrant reserves the right to discontinue that availability at any time.



Item 9.01. Financial Statements and Exhibits.

(d)Exhibits
Exhibit
Number
Description
10.1
Credit Agreement, dated as of July 25, 2025, among Sprouts Farmers Market, Inc., Sprouts Farmers Markets Holdings, LLC, the lenders named therein, JPMorgan Chase Bank, N.A., as administrative agent, an issuing bank and swingline lender, J.P. Morgan Securities LLC, as sustainability structuring agent, Truist Bank and PNC Bank, National Association, as syndication agents, and Bank of America, N.A., BMO Bank, N.A. and US Bank National Association, as documentation agents
99.1
Press release of Sprouts Farmers Market, Inc., dated July 25, 2025, entitled "Sprouts Farmers Market, Inc. Revises Credit Facility"
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPROUTS FARMERS MARKET, INC.
Date: July 25, 2025By:/s/ Brandon F. Lombardi
Name:Brandon F. Lombardi
Title:Chief Legal Officer and Corporate Secretary

Source:

FAQ

How many NTLA shares did the CFO sell in the July 23, 2025 Form 4?

Edward J. Dulac III sold 7,462 common shares at $14.02 each.

Was the NTLA insider sale discretionary?

No. It was a mandatory sell-to-cover transaction to pay taxes on vested RSUs.

What is the CFO鈥檚 remaining NTLA share ownership?

After the sale, he directly holds 106,062 shares.

Did the Form 4 report any option exercises or derivative activity?

No. No derivative securities were acquired or disposed of in this filing.

Does the filing indicate a change in Intellia鈥檚 executive outlook?

The filing is administrative and does not signal any shift in management sentiment.
Stock SFM logo
Sprouts Farmers

NASDAQ:SFM

SFM Rankings

#1010 Ranked by Market Cap
N/A Ranked by Dividends

SFM Latest News

Jul 25, 2025
Sprouts Farmers Market, Inc. Revises Credit Facility
Jul 24, 2025
Broadstone Net Lease Announces Three Additional Build-to-Suit Developments for $61.4 million
Jul 1, 2025
Sprouts Farmers Market to Report Second Quarter 2025 Earnings on July 30, 2025
May 27, 2025
Sprouts Farmers Market to Present at the Deutsche Bank Global Consumer Conference 2025
May 13, 2025
Sprouts Healthy Communities Foundation to Award $3 Million in Grants to Local Organizations Focused on Nutrition, Health, and Wellness

SFM Latest SEC Filings

Jul 23, 2025
[8-K] Sprouts Farmers Market, Inc. Reports Material Event
Jul 9, 2025
[Form 4] Sprouts Farmers Market, Inc. Insider Trading Activity
Jul 7, 2025
[144] Sprouts Farmers Market, Inc. SEC Filing
Jul 1, 2025
[Form 4] Sprouts Farmers Market, Inc. Insider Trading Activity
Jul 1, 2025
[144] Sprouts Farmers Market, Inc. SEC Filing

SFM Stock Data

15.98B
97.39M
0.4%
102.73%
5.7%
Grocery Stores
Retail-grocery Stores
United States
PHOENIX